1.Exercise therapy for diabetes mellitus
Journal of the Korean Medical Association 2023;66(7):427-431
Exercise lowers blood glucose levels, improves insulin sensitivity, and helps prevent complications; therefore, it is highly effective for prevention and treatment of diabetes mellitus. However, many patients with diabetes do not meet the recommendations for the amount of exercise. In this study, we focus on the latest recommendations and discuss exercise therapies that are helpful for patients with diabetes.Current Concepts: Many studies have shown that exercise helps to improve blood glucose control, physical strength, and cardiorespiratory capacity in patients with type 1 or 2 diabetes. Patients with diabetes are advised to perform both aerobic and resistance exercises. Aerobic exercise is suitable for most patients and can rapidly lower blood glucose levels. Resistance exercise improves muscle strength and endurance and is useful for long-term stabilization of blood glucose levels. Combined aerobic and resistance exercise improves insulin resistance and additionally controls blood glucose levels. Patients with diabetes are recommended moderate intensity exercise for at least 150 min/week, at least thrice a week, without interruption in exercise for >2 consecutive days.Discussion and Conclusion: Exercise is an essential recommended lifestyle intervention for patients with diabetes, and regular exercise is important. Furthermore, patients with diabetes should avoid low-energy activities and minimize sitting time.
5.The Effect of Denosumab on Bone Mass in Super Elderly Patients
Journal of Bone Metabolism 2020;27(2):119-124
Background:
Denosumab is a potent antiresorptive drug leading to significant reduction in the risk of vertebral and non-vertebral fractures in postmenopausal osteoporosis. The effect of denosumab in super-elderly patients lacks data to date and few literature has proven the efficacy to this specific group. The purpose of this study was to determine the effectiveness and safety of denosumab in the super-elderly.
Methods:
We retrospectively evaluated 60 patients older than 80 with osteoporosis treated with denosumab. Patients were treated with denosumab every 6 months for 12 months 2017 to 2020. The primary endpoint was defined by the changes in bone mineral density (BMD) of 3 measurement sites: the lumbar spine, femoral neck, and total hip. Changes in bone turnover markers, serum calcium, serum phosphate, and 25-hydroxy-vitamin D were also observed.
Results:
All 60 patients were female, and the mean age was 83.9±3.1, from age 80 to 94. After 12 months of denosumab treatment, significant increases in BMD were observed; 3.02±2.74% for the lumbar spine (P=0.000), 3.10±6.90% for the femoral neck (P=0.005), and 2.89±5.80% for the total hip (P=0.002) The bone turnover marker C-terminal telopeptide of type I collagen and osteocalcin significantly declined after 12 months of treatment (-34.8±45.9%; P=0.002 and –35.5±38.9%; P=0.004 respectively). Symptomatic hypocalcemia and serious adverse drug reactions that required drug discontinuation were not observed during treatment.
Conclusions
Denosumab is thought to be an anti-osteoporotic medication that is sufficiently effective and safe even for the super-elderly.
6.A Case of Ectopic Adrenocorticotropic Hormone Syndrome in Small Cell Lung Cancer.
Chaiho JEONG ; Jinhee LEE ; Seongyul RYU ; Hwa Young LEE ; Ah Young SHIN ; Ju Sang KIM ; Joong Hyun AHN ; Hye Seon KANG
Tuberculosis and Respiratory Diseases 2015;78(4):436-439
Small cell lung cancer (SCLC), which originated from neuroendocrine tissue, can develop into paraneoplastic endocrine syndromes, such as Cushing syndrome, because of an inappropriate secretion of ectopic adrenocorticotropic hormone (ACTH). This paraneoplastic syndrome is known to be a poor prognostic factor in SCLC. The reason for poor survival may be because of a higher risk of infection associated with hypercortisolemia. Therefore, early detection and appropriate treatment for this syndrome is necessary. But the diagnosis is challenging and the source of ACTH production can be difficult to identify. We report a 69-year-old male patient who had severe hypokalemia, metabolic alkalosis, and hypertension as manifestations of an ACTH-secreting small cell carcinoma of the lung. He was treated with ketoconazole and spironolactone to control the ACTH dependent Cushing syndrome. He survived for 15 months after chemotherapy, which is unusual considering the poor outcome of the ectopic ATH syndrome associated with SCLC.
ACTH Syndrome, Ectopic
;
Adrenocorticotropic Hormone*
;
Aged
;
Alkalosis
;
Carcinoma, Small Cell
;
Cushing Syndrome
;
Diagnosis
;
Drug Therapy
;
Humans
;
Hypertension
;
Hypokalemia
;
Ketoconazole
;
Lung
;
Male
;
Paraneoplastic Endocrine Syndromes
;
Paraneoplastic Syndromes
;
Small Cell Lung Carcinoma*
;
Spironolactone
7.The Early Changes in Thyroid-Stimulating Immunoglobulin Bioassay over Anti-Thyroid Drug Treatment Could Predict Prognosis of Graves’ Disease
Jin YU ; Han-Sang BAEK ; Chaiho JEONG ; Kwanhoon JO ; Jeongmin LEE ; Jeonghoon HA ; Min Hee KIM ; Jungmin LEE ; Dong-Jun LIM
Endocrinology and Metabolism 2023;38(3):338-346
Background:
To determine whether baseline thyroid-stimulating immunoglobulin (TSI) bioassay or its early response upon treatment with an anti-thyroid drug (ATD) can predict prognosis of Graves’ disease (GD) in real-world practice.
Methods:
This retrospective study enrolled GD patients who had previous ATD treatment with TSI bioassay checked at baseline and at follow-up from April 2010 to November 2019 in one referral hospital. The study population were divided into two groups: patients who experienced relapse or continued ATD (relapse/persistence), and patients who experienced no relapse after ATD discontinuation (remission). The slope and area under the curve at 1st year (AUC1yr) of thyroid-stimulating hormone receptor antibodies including TSI bioassay and thyrotropin-binding inhibitory immunoglobulin (TBII) were calculated as differences between baseline and second values divided by time duration (year).
Results:
Among enrolled 156 study subjects, 74 (47.4%) had relapse/persistence. Baseline TSI bioassay values did not show significant differences between the two groups. However, the relapse/persistence group showed less decremental TSI bioassay in response to ATD than the remission group (–84.7 [TSI slope, –198.2 to 8.2] vs. –120.1 [TSI slope, –204.4 to –45.9], P=0.026), whereas the TBII slope was not significantly different between the two groups. The relapse/persistence group showed higher AUC1yr of TSI bioassay and TBII in the 1st year during ATD treatment than the remission group (AUC1yr for TSI bioassay, P=0.0125; AUC1yr for TBII,
9.Roles of Follicle-Stimulating Hormone on Bone Metabolism in Late Postmenopausal Women
Chaiho JEONG ; Jinyoung KIM ; Yejee LIM ; Jeonghoon HA ; Mee Kyoung KIM ; Hyuk-Sang KWON ; Ki-Ho SONG ; Moo Il KANG ; Ki-Hyun BAEK
Journal of Bone Metabolism 2022;29(3):175-183
Background:
The effects of elevated follicle-stimulating hormone (FSH) levels on physiological changes in the bone remain unclear. This study aimed to clarify the association between FSH concentrations and bone mineral density (BMD) and bone turnover markers (BTM) in late postmenopausal women.
Methods:
A total of 169 Korean women were enrolled. The participants’ ages ranged from 60 to 84 years (mean age, 69.0±5.1) and reported a mean duration of 19.4±6.6 years since menopause (YSM). The participants showed an average body mass index (BMI) of 24.4±2.8 kg/m2. Age, YSM, estradiol, testosterone, and BMI were confounders in the Pearson's partial correlation. A test for trends across the quartiles of FSH levels was performed for each variable.
Results:
The mean FSH and estradiol concentrations were 61.5 IU/L and 2.9 pg/mL, respectively. Serum FSH concentration was not significantly associated with BMD (lumbar, r=0.09, P=0.30; total hip, r=0.00, P=0.96; and femoral neck, r=0.05, P=0.62). BTM across the FSH quartiles did not show any trend association (bone-specific alkaline phosphate, P=0.31; crosslinked C-terminal telopeptide of type I collagen, P=0.90). Instead, FSH levels were negatively correlated with BMI (r=-0.34, P=0.00). In the multivariate regression model adjusted for age, testosterone, and estradiol, only BMI showed a negative value across the FSH quartiles (β coefficient -0.11, P=0.00).
Conclusions
This study identified that high FSH concentrations were not associated with bone loss or high bone turnover in women in the late postmenopausal period.